Johnson & Johnson (NYSE:JNJ - Get Free Report)'s stock price was down 1.5% during trading on Tuesday. The stock traded as low as $277.56 and last traded at $278.4160. 8,053,708 shares changed hands during mid-day trading, an increase of 1% from the average daily volume of 7,953,780 shares. The stock had previously closed at $282.55.
Key Stories Impacting Johnson & Johnson
Here are a few of the latest stories about JNJ:
- Positive Sentiment: J&J agreed to acquire Ollin for $2.2 billion upfront, with up to about $1.1 billion in additional milestone payments. The deal brings OLN324, a Phase 3 candidate for wet age-related macular degeneration and diabetic macular edema, into J&J’s ophthalmology pipeline. Blackstone Life Sciences will provide $750 million toward Phase 3 development, sharing some development costs and supporting the strategic expansion. J&J to Boost Ophthalmology Pipeline With $2.2B Ollin Acquisition
- Positive Sentiment: UBS views the planned Ollin acquisition as a potential growth driver beyond 2030, reinforcing the deal’s longer-term pipeline rationale. However, OLN324 remains in clinical development and will face competition in a crowded market. UBS on Ollin acquisition
- Negative Sentiment: A Louisiana appeals court upheld a multimillion-dollar verdict in a case alleging J&J talc caused a woman’s mesothelioma and death. The ruling adds to ongoing litigation risk and could weigh on investor sentiment. Louisiana Appeals Court Upholds Damages in Mesothelioma Case
Wall Street Analysts Forecast Growth
Several analysts recently commented on JNJ shares. Royal Bank Of Canada lowered their target price on Johnson & Johnson from $290.00 to $280.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 14th. JPMorgan Chase & Co. boosted their price target on Johnson & Johnson from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 29th. UBS Group set a $270.00 price target on Johnson & Johnson in a research note on Wednesday, October 14th. Citigroup increased their price target on Johnson & Johnson from $298.00 to $303.00 and gave the stock a "buy" rating in a research note on Monday, October 5th. Finally, TD Cowen reissued a "buy" rating on shares of Johnson & Johnson in a report on Tuesday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company's stock. According to MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average target price of $275.92.
View Our Latest Stock Report on Johnson & Johnson
Johnson & Johnson Price Performance
The stock has a market capitalization of $670.23 billion, a price-to-earnings ratio of 42.18, a P/E/G ratio of 2.80 and a beta of 0.22. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The business has a 50-day simple moving average of $267.12 and a two-hundred day simple moving average of $250.12.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The business had revenue of $25.40 billion during the quarter, compared to analysts' expectations of $25.38 billion. During the same quarter last year, the business posted $2.80 earnings per share. The company's quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, research analysts predict that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 1.9%. Johnson & Johnson's payout ratio is 81.21%.
Insider Buying and Selling at Johnson & Johnson
In other news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Elizabeth Forminard sold 13,072 shares of the firm's stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $284.39, for a total value of $3,717,546.08. Following the sale, the executive vice president directly owned 16,994 shares of the company's stock, valued at approximately $4,832,923.66. This represents a 43.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.16% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Johnson & Johnson
Several hedge funds have recently modified their holdings of JNJ. Prestige Wealth Management Group LLC boosted its position in Johnson & Johnson by 14.2% during the 3rd quarter. Prestige Wealth Management Group LLC now owns 37,886 shares of the company's stock worth $10,030,000 after acquiring an additional 4,713 shares during the period. Prowell Financial Management purchased a new stake in shares of Johnson & Johnson in the third quarter worth approximately $265,000. Pure Financial Advisors LLC lifted its position in shares of Johnson & Johnson by 11.2% in the third quarter. Pure Financial Advisors LLC now owns 32,461 shares of the company's stock worth $8,594,000 after purchasing an additional 3,262 shares in the last quarter. Aspen Grove Capital LLC lifted its position in shares of Johnson & Johnson by 10.7% in the third quarter. Aspen Grove Capital LLC now owns 3,585 shares of the company's stock worth $949,000 after purchasing an additional 347 shares in the last quarter. Finally, Bamco Inc. NY boosted its holdings in shares of Johnson & Johnson by 12.3% during the third quarter. Bamco Inc. NY now owns 28,269 shares of the company's stock worth $7,484,000 after purchasing an additional 3,097 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.